Takeda looks to jump-start its AI drug development efforts with Numerate, a well-positioned start-up in the field

June 05, 2018 | Case Study

Takeda Pharmaceutical is Japan's largest drug company, and, with more than $15 billion in annual revenues, is also among the largest in the world. Therapeutic focus areas for the company include neuroscience, gastroenterology, oncology, and vaccines, and the firm is continuing to try to build out its drug pipeline in those areas. Historically, the company has done so via acquisitions, including recently spending billions of dollars buying companies like Ariad Pharmaceuticals, TiGenix, and Shire. The 230-year-old company is increasingly focused on digital transformation, with its chief digital officer, Bruno Villetelle, noting that it aims to become the industry's digital health leader by 2025, including by pursuing external collaborations.

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Sign In

Interested in Learning More?

Contact us to learn the benefits of becoming a Lux member.

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978